I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmablast | 6 studies | 46% ± 23% | |
| T cell | 6 studies | 48% ± 8% | |
| B cell | 5 studies | 30% ± 5% | |
| pro-B cell | 5 studies | 25% ± 3% | |
| natural killer cell | 5 studies | 36% ± 17% | |
| CD8-positive, alpha-beta T cell | 5 studies | 49% ± 15% | |
| transit amplifying cell | 4 studies | 40% ± 11% | |
| epithelial cell | 4 studies | 27% ± 13% | |
| effector CD8-positive, alpha-beta T cell | 4 studies | 50% ± 23% | |
| CD4-positive, alpha-beta T cell | 4 studies | 58% ± 10% | |
| plasma cell | 3 studies | 34% ± 2% | |
| hematopoietic precursor cell | 3 studies | 26% ± 3% | |
| erythrocyte | 3 studies | 35% ± 15% |
